Zobrazeno 1 - 10 of 25 pro vyhledávání: '"W. Steve Ammons"'
1
Akademický článek
A Novel Alkylating Agent, Glufosfamide, Enhances the Activity of Gemcitabine In Vitro, In Vivo
Autor: W. Steve Ammons, Jin-Wei Wang, Zhijian Yang, George F. Tidmarsh, Robert M. Hoffman
Publikováno v: Neoplasia: An International Journal for Oncology Research, Vol 9, Iss 8, Pp 625-633 (2007)
Glufosfamide is an alkylating agent consisting of iphosphoramide mustard conjugated to glucose that is currently included in clinical studies of pancreatic cancer. We studied the effects of glufosfamide, in combination with gemcitabine, on in vitro,
Externí odkaz: https://doaj.org/article/79a178d1594a4dfb8bbe9eca69de9786
Zobrazit plný text záznamu
2
Akademický článek
ING-1(heMAb), a Monoclonal Antibody to Epithelial Cell Adhesion Molecule, Inhibits Tumor Metastases in a Murine Cancer Model
Autor: Harry H. Ruan, Kristen R. Scott, Eddie Bautista, W. Steve Ammons
Publikováno v: Neoplasia: An International Journal for Oncology Research, Vol 5, Iss 6, Pp 489-494 (2003)
ING-1(heMAb), a human-engineered monoclonal antibody (MAb) that specifically targets the epithelial cell adhesion molecule (Ep-CAM), kills adenocarcinoma cells in vitro and inhibits tumor growth in vivo. In the current study, we evaluated the efficac
Externí odkaz: https://doaj.org/article/7005ae2224884dcf9ef771dac345907a
Zobrazit plný text záznamu
3
Akademický článek
In Vitro and In Vivo Pharmacology and Pharmacokinetics of a Human Engineered™ Monoclonal Antibody to Epithelial Cell Adhesion Molecule
Autor: W. Steve Ammons, Robert J. Bauer, Arnold H. Horwitz, Zhi J. Chen, Eddie Bautista, Harry H. Ruan, Marina Abramova, Kristen R. Scott, Russell L. Dedrick
Publikováno v: Neoplasia: An International Journal for Oncology Research, Vol 5, Iss 2, Pp 146-154 (2003)
ING-1(heMAb), a Human Engineered™ monoclonal antibody to epithelial cell adhesion molecule (Ep-CAM ), was evaluated for its in vitro and in vivo activity. The dissociation constant of ING-1(heMAb) for binding to Ep-CAM on HT-29 human colon tumor ce
Externí odkaz: https://doaj.org/article/b4ec14f2d88f4787824412af41c6a203
Zobrazit plný text záznamu
5
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules
Autor: Yan Wang, Damien Ferraro, Dharmendra Ahluwalia, W. Steve Ammons, Mark D. Matteucci, Lee D. Cranmer, Jian Xin Duan, Jessica D Sun, John G. Curd, Charles P. Hart, Qian Liu, Amanda F. Baker, Jingli Wang
Publikováno v: Cancer Chemotherapy and Pharmacology. 69:1487-1498
Subregional hypoxia is a common feature of tumors and is recognized as a limiting factor for the success of radiotherapy and chemotherapy. TH-302, a hypoxia-activated prodrug selectively targeting hypoxic regions of solid tumors, delivers a cytotoxic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fd42d9f797424a8f6e4333a6d6351a1
https://doi.org/10.1007/s00280-012-1852-8
Zobrazit plný text záznamu
6
Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
Autor: W. Steve Ammons, Damien Ferraro, Jingli Wang, Qian Liu, Yan Wang, Charles P. Hart, Dharmendra Ahluwalia, Jian-Xin Duan, John G. Curd, Mark D. Matteucci, Jessica D Sun
Publikováno v: Clinical Cancer Research. 18:758-770
Purpose: Tumor hypoxia underlies treatment failure and yields a more aggressive, invasive, and metastatic cancer phenotype. TH-302 is a 2-nitroimidazole triggered hypoxia-activated prodrug of the cytotoxin bromo-isophosphoramide mustard (Br-IPM). The
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c65d1b1f4b21b090fd54e26f2f950006
https://doi.org/10.1158/1078-0432.ccr-11-1980
Zobrazit plný text záznamu
7
A Novel Alkylating Agent, Glufosfamide, Enhances the Activity of Gemcitabine In Vitro, In Vivo
Autor: Jinwei Wang, Zhijian Yang, George F. Tidmarsh, Robert M. Hoffman, W. Steve Ammons
Publikováno v: Neoplasia: An International Journal for Oncology Research, Vol 9, Iss 8, Pp 625-633 (2007)
Glufosfamide is an alkylating agent consisting of iphosphoramide mustard conjugated to glucose that is currently included in clinical studies of pancreatic cancer. We studied the effects of glufosfamide, in combination with gemcitabine, on in vitro a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b461a75dfbf8c698765c873496f45638
https://doi.org/10.1593/neo.07343
Zobrazit plný text záznamu
8
rBPI(10—193) is secreted by CHO cells and retains the activity of rBPI21
Autor: Rossana Nadell, Arnold Horwitz, Russell L. Dedrick, Robert E. Williams, W. Steve Ammons, Robert J. Bauer, Pei-Syan Liu
Publikováno v: Journal of Endotoxin Research. 10:97-106
rBPI23, a recombinant N-terminal fragment of human bactericidal/permeability-increasing protein (BPI), kills Gram-negative bacteria and neutralizes endotoxin. rBPI21, a variant in which cysteine 132 is changed to alanine, retains the activities of rB
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0fe53ae31aebeb5542a2774cd10279a5
https://doi.org/10.1177/09680519040100020501
Zobrazit plný text záznamu
10
Recombinant Bactericidal/Permeability-Increasing Protein (rBPI21) for Treatment of Parvovirus Enteritis: A Randomized, Double-Blinded, Placebo-Controlled Trial
Autor: Cynthia M. Otto, W. Steve Ammons, Emily J. Rogell, Richard B. Prior, C. Bisque Jackson
Publikováno v: Journal of Veterinary Internal Medicine. 15:355-360
We evaluated the ability of an antimicrobial and endotoxin-neutralizing agent, the recombinant amino terminal fragment of bactericidal permeability-increasing protein (rBPI21), to decrease plasma endotoxin concentration and severity of clinical signs
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::09fc55724598a5f306513ad3ff903715
https://doi.org/10.1111/j.1939-1676.2001.tb02329.x
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje